Rhythm Pharmaceuticals, Inc. (RYTM) — Stock Score Summary

Rhythm Pharmaceuticals, Inc. (RYTM) has a MoatMap StockRank of 23/100 based on Quality (33/100), Value (34/100), and Momentum (44/100) factor scores. The current signal is SELL. Rhythm Pharmaceuticals is a commercial-stage biopharmaceutical company. It is highly dependent on a single drug (setmelanotide) and lacks the diversified, asset-light cash flows required by our quality compounder framework.

Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company dedicated to the development and commercialization of therapies for rare genetic diseases of obesity. Its flagship product, Imcivree (setmelanotide), is an FDA-approved MC4R agonist designed to restore weight control in patients with specific genetic mutations. The company holds a dominant niche position as a pioneer in precision medicine for melanocortin-4 receptor pathway disorders.

Key Financial Metrics

Price$87.86
Market Cap$6.4B
P/E (Forward)-110.29
Price/Book42.34
Return on Equity-101.2%
Return on Invested Capital-46.9%
Debt/Equity47.26
Gross Margin89.4%
Operating Margin-87.1%
Revenue Growth83.8%
Free Cash Flow$-151M

Rhythm Pharmaceuticals, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Rhythm Pharmaceuticals, Inc.’s (RYTM) StockRank?
MoatMap’s StockRank for Rhythm Pharmaceuticals, Inc. (RYTM) is 23/100, with a Sell signal. It is a composite of Quality (33), Value (34), and Momentum (44) factor ranks across MoatMap’s 19,000+ stock universe.
Does Rhythm Pharmaceuticals, Inc. have an economic moat?
Rhythm Pharmaceuticals, Inc. (RYTM) has a Quality factor score of 33/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Rhythm Pharmaceuticals, Inc. a buy, hold, or sell?
MoatMap’s current signal for Rhythm Pharmaceuticals, Inc. (RYTM) is Sell, based on a StockRank of 23/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Rhythm Pharmaceuticals, Inc. in?
Rhythm Pharmaceuticals, Inc. (RYTM) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksRYTM deep dive reportAI ChampionsHow we score stocksSense-check another stock